Sanofi

STOCKHOLM, Dec. 5, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced its participation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place on 6 – 9 December in Orlando, Florida. At this year's meeting, Sobi will showcase its commitment to advancing care in haematology with 19 scientific abstracts, including two oral presentations. These feature the most recent clinical data and insights from completed and ongoing studies across Sobi's innovative portfolio including data from efanesoctocog alfa, pegcetacoplan, avatrombopag, emapalumab, and pacritinib. These presentations underscore Sobi's mission to deliver life-changing therapies for patients with rare and severe blood disorders. "We will present evidence at ASH from a post hoc analysis demonstrating that pacritinib reduces or stabilises spleen size, improves haematologic parameters, and lessens myelofibrosis symptoms in patients with highrisk disease. These findings matter because they address key drivers of morbidity which affect daytoday functioning and quality of life. The ASH meeting also offers an opportunity to discuss the latest research on emapalumab, efanesoctocog alfa, pegcetacoplan, avatrombopag, as well as loncastuximab tesirine," said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. Summary of full Sobi data to be presented at ASH 2025: Overview of treatment advances with complement Inhibitors in patients with Paroxysmal Nocturnal Haemoglobinuria. Optimising PNH treatment with the complement inhibitor Pegcetacoplan: A case report. User experience with Pegcetacoplan on-body Injector in patients with Paroxysmal Nocturnal Hemoglobinuria. About ALTUVOCT ® (efanesoctocog alfa) ALTUVOCT ® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (HA). ALTUVOCT can be used for all age groups and any disease severity. About the Sobi and Sanofi Collaboration Sobi and Sanofi collaborate on the development and commercialisation of ALTUVOCT® (efanesoctocog alfa), or ALTUVIIIO™ in the US. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. About Aspaveli®/Empaveli® (pegcetacoplan) Aspaveli/Empaveli (pegcetacoplan) is a targeted C3 and C3b inhibitor designed to regulate excessive activation of the complement cascade, part of the body's immune system, which can lead to the onset and progression of many serious diseases. Aspaveli/Empaveli is approved for the treatment of adults with paroxysmal nocturnal haemoglobinuria (PNH) in the US, European Union, and other countries globally, and for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in the United States. It is under regulatory review for C3G and primary IC-MPGN in the European Union and other countries globally. About the Sobi and Apellis Collaboration Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialisation rights for systemic pegcetacoplan, and its opt-in rights for future development programs are unchanged, exercisable at any time prior to commercialisation. Apellis has exclusive U.S. commercialisation rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy. About Doptelet® (avatrombopag) Doptelet (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) scheduled to undergo an invasive procedure. Doptelet is also approved for the treatment of chronic ITP in pediatric patients. About Gamifant® (emapalumab-lzsg) Gamifant is an anti-IFNγ antibody that binds free and receptor-bound IFNγ, which when secreted in an uncontrolled manner can cause hyperinflammation. Gamifant is indicated for intravenous infusion over one hour and is FDA approved for the treatment of primary hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) in Still's disease. About Vonjo® (pacritinib) Vonjo (pacritinib) is a kinase inhibitor indicated in the United States for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials. Vonjo is also being investigated for other rare hematologic conditions, including VEXAS syndrome. Sobi® Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information was brought to you by Cision The following files are available for download: 21% more press release views with Request a Demo

California-based Artera.io , which utilizes humans and AI agents for patient communications, has secured $65 million in growth investment and will have $100 million in Contracted Annual Recurring Revenue (CARR) by the end of the year. Existing investors participated in the round, including Lead Edge Capital (lead investor), Health Velocity Capital, Heritage Medical Systems and Jackson Square Ventures. The company will use the funds to scale its business. "The race to leverage Agentic AI in healthcare will not be won with technology alone; building AI agents is quickly becoming commoditized," Guillaume de Zwirek, CEO and cofounder of Artera.io, said in a statement. "Success requires technology paired with deep domain experience, extensive real-world data and distribution channels that allow for quick and easy activation." Angle Health , a health insurance and benefits provider, raised $58 million in Series A funding, which includes a combination of debt and equity. The round brings the California-based company's total raise to $200 million. Portage led the round, with participation from SixThirty Ventures, Crew Capital, PruVen Capital, Mighty Capital, Aloft VC, Wing Venture Capital, Mindset Ventures, Wormhole Capital and Waseem Daher, founder of Pilot, the accounting services company for technology startups. "The healthcare benefits ecosystem wasn't designed for the small-to-medium-sized businesses that employ nearly half of America's workforce, and legacy technology can't deliver on the efficiencies and savings unlocked by AI," Ty Wang, cofounder and CEO of Angle Health, said in a statement. "We're rebuilding healthcare infrastructure and care pathways to give all employers access to the comprehensive benefits historically reserved for large enterprises." Trial Library, which uses AI to recruit and retain participants for clinical trials, has secured $10 million in Series A funding, bringing its total raise to $15 million. The round was co-led by SemperVirens Venture Capital and Next Ventures, with participation from Sanofi Ventures, Civilization Ventures, How Women Invest, Overwater Ventures, Lux Capital and others. The company, which launched in 2022, partners with community healthcare providers to help connect patients to clinical trials. Trial says it partners with global biopharmaceutical companies to accelerate research and development and enrollment. "Trial Library is the first technology company to unlock the payer market to effectively broaden the pool of patients who are considered for clinical trials," Allison Baum Gates, general partner of SemperVirens Venture Capital, said in a statement. "We're excited to back a platform that aligns incentives and unites patients, providers, payers, and life-science partners around shared cost-savings and patient outcomes."

The UK’s National Institute for Health and Care Excellence (NICE) told stakeholders this week that previously rejected drugs won’t automatically fall under its new cost-effectiveness threshold. Further, medicines currently under review that would now be covered by the new £35,000 limit will have their decisions delayed until April, according to a Thursday email seen by Endpoints News . After ongoing negotiations with the US government, the UK announced last week it was raising its cost-effectiveness threshold for drugs by 25%. Currently, the upper threshold limit is £30,000, but this will be raised to £35,000, meaning an additional three to five drugs or label expansions will be recommended per year. It’s currently unclear which drugs would benefit from this future update, but meetings are expected to be set after April. One possible candidate could be the myeloma combo treatment called IsaPd, which is a combination of Sanofi’s Sarclisa, Bristol Myers Squibb’s Imnovid (sold as Pomalyst in the US) and dexamethasone. It is currently being reevaluated by NICE, with a decision expected in March. IsaPd was initially rejected in June 2024 for being too costly, but NICE reconsidered after an appeal by patient advocacy groups. In an unusual move, the regulation change will be handled by the Department of Health and Social Care, which will meet this month to discuss changing the threshold. NICE will then meet early next year to implement the change, according to the email. In the email, NICE representatives underscored “they weren’t responsible for the decision” to change the threshold limit and refused to talk about the rationale behind the policy change. NICE will be hosting a board meeting in December to review the threshold change, which will be effective in April.